VIDEO: New CREDENCE data demonstrates CV, renal benefit in primary prevention population
SAN FRANCISCO — In this video exclusive, Kenneth W. Mahaffey, MD, vice chair of clinical research in the department of medicine at Stanford School of Medicine and director of the Stanford Center for Clinical Research, discusses new subgroup analyses from the phase 3 CREDENCE study, a large dedicated renal outcomes trial in patients with type 2 diabetes and chronic kidney disease.
In new subgroup analyses presented Tuesday, researchers demonstrated that canagliflozin (Invokana, Janssen) was associated with a statistically significant and clinically important reduction in both renal and CV outcomes in patients with type 2 diabetes and CKD — with and without a history of CVD — when compared with similar patients assigned placebo, Mahaffey said.
“This is the first time with an antidiabetic drug in type 2 diabetes with chronic kidney disease that the drug has been shown to reduce cardiovascular and renal outcomes in a primary prevention group,” Mahaffey said. “These findings are incredibly important for patients with type 2 diabetes and chronic kidney disease and the physicians and clinicians taking care of them.”
Watch the video for more.